Published: December 2022
The product-related R&D funding flows for neglected diseases are collected from the Policy Cures Research G-FINDER survey. For 2020, funding data were collected from private, public and philanthropic organizations, on all types of product-related R&D, basic research and platform technology covering neglected diseases (note: the disease names have been reclassified here, see the classifications and standards section for the rationale and approach).
See also:
What you see | Scope and limitations | Data sources | Previous Versions
The data visualization illustrates funding trends by year, and % differences with the previous year (chart A), by disease (chart B), and type of R&D (chart C) for the period 2007-2020. All funding data has been adjusted for inflation, and is reported in 2020 US dollars (US$) (adjustment performed by the data source).
The data must be interpreted cautiously because of the specific scope restrictions of the G-FINDER survey (see link below for detail). The scope of the G-FINDER survey is determined by applying the following three criteria for neglected diseases. (R&D investments which do not meet these criteria are excluded.)
In addition, the funding data from industry is presented in an aggregated form for confidentiality. This means that funding levels by disease and R&D category substantially underestimate the actual investments in these diseases within the scope of G-FINDER described above.
The COVID-19 pandemic slightly altered the participation in the 2019 G-Finder survey, which meant that some of the reduction in funding in the previous analysis was the result of the reduced reporting rather than an actual drop in funding. In the 2020 report, some of these 2019 figures were reviewed to correct these drops and supersede the numbers presented in previous analysis.
Histoplasmosis (here under Mycoses) and scabies were added to the G-Finder survey scope. This includes R&D for all product categories for both diseases, all basic research for histoplasmosis and basic research that is explicitly targeted at low- and middle-income country (LMIC)-related disease burden for scabies. LMIC-focused basic research on rotavirus and Enterotoxigenic E. coli (both under Diarrhoeal diseases) were also included. And restriction requiring hepatitis C vaccine R&D to be LMIC-specific has been relaxed. This increase in scope accounts for no more than 0.2% of global funding in 2020.
November 2021 | April 2020 | February 2019 | January 2018 | April 2017 | January 2017